Introduction
Evidence & Practice Previous     Next

Introduction

Diana Borthwick Lung cancer nurse specialist, Edinburgh Cancer Centre, Edinburgh
Lavinia Magee Nurse consultant thoracic oncology, Papworth Hospital NHS Foundation Trust, Cambridge
Sarah Smith Lung cancer nurse specialist, North Bristol NHS Trust, Bristol
Rachel Thomas Lung cancer nurse specialist, Guy’s and St Thomas’ NHS Foundation Trust, London

Lung cancer is the most common cause of cancer mortality in the UK, accounting for more than one in five cancer deaths (Cancer Research UK 2016). Within that number, 85-90% of cases are non-small cell lung cancer (NSCLC) (Reck et al 2014) and, in around 5% of those cases, patients are found to carry a translocation in the anaplastic lymphoma kinase (ALK) gene (Shaw et al 2014). Patients who test positive for this translocation (ALK+) can be treated with ALK inhibitors. While the first-generation ALK inhibitor crizotinib may be effective initially, many patients with advanced ALK+ NSCLC develop resistance and experience disease progression during treatment (Shaw et al 2014).

Cancer Nursing Practice. 15, 10,25-25. doi: 10.7748/cnp.2016.e1364a

Correspondence

Diana.Borthwick@nhslothian.scot.nhs.uk

Peer review

This article has been subject to external double-blind peer review and checked for plagiarism using automated software

Conflict of interest

This supplement has been commissioned and paid for by Novartis. Novartis has funded medical writing support through Nyxeon Healthcare Communications and payment to the journal for advertorial space. All authors contributed equally to the development, design and review of this article; Novartis has reviewed and approved the content

Received: 30 September 2016

Accepted: 07 November 2016